ERBB2 and cancer: No significant increased risk was seen in the HER2+(ER−) subtype when compared to Luminal B HER2 cancers for either 5-year DFS (HR 1.31, 95% CI 0.42–4.1) or 5-year OS (HR 2.18, 95% CI 0.79–6.03) (Table S1).